The two funds will back about 30 portfolio companies, and the Dutch investor is expanding its Danish footprint through deals tied to Novo Holdings.
MedWatch reports on Forbion’s €2.3 billion fundraising across Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII. The raise brings Forbion’s assets under management to approximately €7.5 billion and gives the two funds capacity to finance around 30 companies. Forbion
The funds invest at different stages of biotech development: Growth Opportunities Fund IV focuses primarily on later-stage biopharma companies in Europe and North America, while Ventures Fund VIII backs therapeutics-focused companies and new ventures built around promising assets and experienced teams.
The fundraising strengthens Forbion’s capacity to back innovative European biotech while maintaining a selective approach to investing in companies developing medicines for significant unmet medical needs.